Creative Biolabs Develops High-quality Duocarmycin-linker Complexes of Antibody-drug Conjugates

New York, January 17, 2019—With the well-established “DrugLnk” organic synthesis platform, Creative Biolabs now releases duocarmycins for the development of antibody-drug conjugates.


Antibody-drug conjugates, the next-generation targeted anti-tumor agents, consist of the covalent coupling of a monoclonal antibody with a cytotoxic payload drug via a small molecular linker, in which the payload drug plays an essential role in dictating its efficacy.


A suitable payload should be small in size to minimize the risk of immunogenicity and is supposed to exert adequate plasma stability to maintain drug efficacy before reaching the target. Based on this standard, many payloads have been identified and developed into ADCs and their major intracellular targets include microtubule, DNA, as well as DNA transcription machineries.


“To satisfy our customers’ unique needs for different ADC development projects, we established an exclusive “DrugLnk” organic synthesis platform with a large collection of payload drugs and linkers. We are highly experienced in full chemical synthesis, chemical modification, as well as bio-conjugation and can help our clients prepare innovated payload-linker complexes for novel ADC developments, such as duocarmycin”, said the scientist from Creative Biolabs.


Duocarmycin is an excellent candidate as payloads that yields ADCs with maximized cell-killing potency for regular and more importantly, multi-drug resistant cancer cells. Based on our well-established platform, we can develop high quality antibody-drug conjugates (ADCs) duocarmycin-linker complexes using readily available or customized linkers for antibody conjugation in a timely and cost-effective manner for targeted anti-cancer therapies and a variety of other applications.”


The seasoned scientists here at Creative Biolabs is dedicated to tailoring customized services and high-quality products to contribute greatly to the success of customers’ either scientific or industrial projects. Please find more information about antibody-drug conjugates on the company website. 



Author Bio

With more than a decade of exploration and expansion, Creative Biolabs provides current research and service capacity that covers the entire new drug discovery and development pipeline, ranging from early discovery, pre-clinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, Creative Biolabs established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with customers and research partners to develop new medicines for a better, healthier world. After years of pursuit for perfection, Creative Biolabs has established leadership in targeted immunotherapy and antibody-drug conjugate (ADC) development. They offer customers comprehensive one-stop-shop of all aspects in ADC research and evaluation, ranging from antigen selection, antibody production/optimization, payload-linker synthesis, ADC conjugation, to various stages of ADC characterization and pre-clinical evaluation.



Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States